Quabodepistat (OPC-167832) is a molecule with a new mechanism of action that has potent antituberculosis activity and a favourable safety profile. It is being studied as part of a new TB regimen, in combination with delamanid and bedaquiline, under the Project to Accelerate New Treatments for Tuberculosis (PAN-TB) program.